Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:ESPR NASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.64-1.3%$7.50$5.90▼$29.61$568.25M2.381.28 million shs1.51 million shsESPREsperion Therapeutics$2.77-0.4%$1.89$0.69▼$3.94$560.51M0.895.84 million shs4.90 million shsORKAOruka Therapeutics$14.90-2.4%$14.69$5.49▼$31.13$571.50M-0.26131,850 shs134,754 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%-2.52%+9.17%+3.48%-69.10%ESPREsperion Therapeutics-2.11%+10.76%+35.61%+155.05%+45.55%ORKAOruka Therapeutics-0.91%-3.42%-0.72%+27.49%-38.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.64-1.3%$7.50$5.90▼$29.61$568.25M2.381.28 million shs1.51 million shsESPREsperion Therapeutics$2.77-0.4%$1.89$0.69▼$3.94$560.51M0.895.84 million shs4.90 million shsORKAOruka Therapeutics$14.90-2.4%$14.69$5.49▼$31.13$571.50M-0.26131,850 shs134,754 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%-2.52%+9.17%+3.48%-69.10%ESPREsperion Therapeutics-2.11%+10.76%+35.61%+155.05%+45.55%ORKAOruka Therapeutics-0.91%-3.42%-0.72%+27.49%-38.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$19.76158.68% UpsideESPREsperion Therapeutics 2.80Moderate Buy$7.00152.71% UpsideORKAOruka Therapeutics 3.29Buy$40.33170.69% UpsideCurrent Analyst Ratings BreakdownLatest PTNT, ORKA, ESPR, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.008/12/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$40.008/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $16.008/7/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $15.007/23/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.007/21/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$40.006/17/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.13N/AN/A$8.17 per share0.94ESPREsperion Therapeutics$332.31M1.68$0.02 per share115.71($1.97) per share-1.41ORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)ESPREsperion Therapeutics-$51.74M-$0.49N/AN/A62.44-35.84%-0.91%-28.41%11/6/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)Latest PTNT, ORKA, ESPR, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025ORKAOruka Therapeutics-$0.48-$0.46+$0.02-$0.46N/AN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.645.64ESPREsperion TherapeuticsN/A1.150.76ORKAOruka TherapeuticsN/A27.4227.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%ESPREsperion Therapeutics47.39%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%ESPREsperion Therapeutics1.70%ORKAOruka Therapeutics24.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42073.42 million69.95 millionOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableORKAOruka TherapeuticsN/A37.45 million28.20 millionN/APTNT, ORKA, ESPR, and ARVN HeadlinesRecent News About These CompaniesOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 5.4% - Here's What HappenedSeptember 14 at 3:40 PM | marketbeat.comBrokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Price Target at $40.38September 6, 2025 | americanbankingnews.comOMERS ADMINISTRATION Corp Has $461,000 Holdings in Oruka Therapeutics, Inc. $ORKASeptember 5, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Shares Up 6.6% - Time to Buy?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases Shares of 132,780 Oruka Therapeutics, Inc. $ORKASeptember 4, 2025 | marketbeat.comRedmile Group LLC Cuts Position in Oruka Therapeutics, Inc. $ORKASeptember 4, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 4, 2025 | marketbeat.comBraidwell LP Raises Stake in Oruka Therapeutics, Inc. $ORKASeptember 3, 2025 | marketbeat.comOruka Therapeutics, Inc. $ORKA Shares Bought by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 5.8% - What's Next?August 27, 2025 | marketbeat.comCandriam S.C.A. Purchases Shares of 116,698 Oruka Therapeutics, Inc. $ORKAAugust 26, 2025 | marketbeat.comQ3 EPS Forecast for Oruka Therapeutics Decreased by AnalystAugust 22, 2025 | marketbeat.comOruka Therapeutics initiated with a Buy at Clear StreetAugust 21, 2025 | msn.comOruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from HC WainwrightAugust 20, 2025 | marketbeat.comOruka Therapeutics (ORKA) Receives a Buy from H.C. WainwrightAugust 19, 2025 | theglobeandmail.comWedbush Forecasts Reduced Earnings for Oruka TherapeuticsAugust 17, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Downgraded by Wall Street Zen to "Sell"August 17, 2025 | marketbeat.comQ3 EPS Forecast for Oruka Therapeutics Reduced by AnalystAugust 16, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Is In A Good Position To Deliver On Growth PlansAugust 15, 2025 | finance.yahoo.comOruka Therapeutics reports Q2 EPS (46c), consensus (43c)August 12, 2025 | msn.comOruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTNT, ORKA, ESPR, and ARVN Company DescriptionsArvinas NASDAQ:ARVN$7.64 -0.10 (-1.29%) Closing price 04:00 PM EasternExtended Trading$7.63 -0.01 (-0.14%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Esperion Therapeutics NASDAQ:ESPR$2.77 -0.01 (-0.36%) Closing price 04:00 PM EasternExtended Trading$2.78 +0.01 (+0.36%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Oruka Therapeutics NASDAQ:ORKA$14.90 -0.36 (-2.36%) Closing price 04:00 PM EasternExtended Trading$14.88 -0.03 (-0.17%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
